Study debunks belief insulin puts people with diabetes at risk of heart disease

June 11, 2012

Researchers at McMaster University have discovered that long-term insulin use does not harm people with diabetes or pre-diabetes or put them at risk of heart attacks, strokes or cancer.

This is contrary to concerns that long-term use of insulin may cause heart disease, says Dr. Hertzel Gerstein, principal investigator of the study, professor of medicine at McMaster's Michael G. School of Medicine and deputy director of the Population Health Research Institute at McMaster University and Hamilton Health Sciences.

"People have been debating the question of whether there are adverse consequences to long-term insulin use for years," he said. "This study provides the clearest answer yet to that question: No, there are not."

Gerstein is scheduled to present the findings of the ORIGIN study (Outcome Reduction with an Initial Glargine ), today at the scientific sessions of the in Philadelphia. The results are also published today in two papers in the medical journal (NEJM).

The video will load shortly.

A second important finding of the study is that people with pre-diabetes who received daily basal with insulin glargine had a 28 per cent lower chance of developing type 2 diabetes, even after the injections stopped.

Gerstein jointly led the study with Dr. Salim Yusuf, professor of medicine and director of the Population Health Research Institute.

Today, more than nine million Canadians are living with diabetes or pre-diabetes. Diabetes is a , often debilitating and sometimes fatal disease, in which the body either cannot produce insulin or cannot properly use the insulin it produces. This leads to high levels of glucose in the blood which can damage organs, blood vessels and nerves. The body needs insulin to use glucose as a source of energy.

In the ORIGIN study, more than 12,500 people at 537 sites in 40 countries with an average age of 64, who are at high risk for, or in the early stages of type 2 , were randomized to either one daily injection of insulin (glargine) or no insulin (standard care) for an average of six years.

Researchers found no difference among the two groups in cardiovascular outcomes or in the development of any type of cancer. This suggests daily insulin injections (with ) to normalize glucose levels are not harmful when taken over long periods of time. Throughout the study, most of the participants given insulin maintained normal fasting glucose levels (below 6 mmol/l).

The study confirmed the presence of two previously known side effects of insulin – hypoglycemia (low blood sugar) and modest weight gain. Both were considered minor from a medical point of view, with participants gaining an average of 3.5 pounds during the study and experiencing a low, 0.7 per cent higher risk of severe hypoglycemia per year than the people not on insulin.

"We now know what the risks are of taking on a long-term basis, and they are low," Gerstein said.

The study also discovered that daily doses of one-gram omega-3 fatty acid capsules did not prevent cardiac-related deaths in people with or prediabetes.

"There was neither benefit nor harm in the participants who were studied," said Jackie Bosch, associate professor of McMaster's School of Rehabilitation Science and project manager for the trial. "However, the effect of these supplements in other groups, and the effect of a diet rich in omega 3 fatty acids was not studied."

Explore further: Automatic suspension of insulin delivery via insulin pumps reduces hypoglycemia

Related Stories

Automatic suspension of insulin delivery via insulin pumps reduces hypoglycemia

February 9, 2012
An automated on/off feature built into insulin pump systems can suspend insulin delivery when it detects low blood glucose levels (via continuous glucose monitoring), significantly reducing the severity and duration of hypoglycemia ...

Patients with Type 2 diabetes may not benefit from oral medication as well as insulin

April 20, 2012
Patients suffering from type 2 diabetes may not benefit from taking both an oral glucose lowering drug (metformin) and insulin instead of insulin alone, a study published on bmj.com claims.

Recommended for you

Diabetes pill might replace injection to control blood sugar

October 17, 2017
(HealthDay)— An injectable class of diabetes medication—called glucagon-like peptide-1 or GLP-1—might one day be available in pill form, research suggests.

Skimping on sleep may contribute to gestational diabetes

October 17, 2017
The amount of time spent sleeping in the United States has dropped significantly in the past twenty years with almost a quarter of women and 16 percent of men experiencing insufficient sleep. Now, a new study has found that ...

Artificial pancreas performs well in clinical trial

October 16, 2017
During more than 60,000 hours of combined use of a novel artificial pancreas system, participants in a 12-week, multi-site clinical trial showed significant improvements in two key measures of well-being in people living ...

Omega-6 fats may help prevent type 2 diabetes

October 11, 2017
The risk of developing type 2 diabetes could be significantly reduced by eating a diet rich in omega-6 polyunsaturated fats, a new study suggests.

Where there's type 1 diabetes, celiac disease may follow

October 10, 2017
(HealthDay)—Parents of young children with type 1 diabetes need to be on the lookout for symptoms of another autoimmune condition—celiac disease, new research suggests.

Type 1 diabetes and the microbiota—MAIT cells as biomarkers and new therapeutic targets

October 10, 2017
Together with colleagues from AP-HP Necker–Enfants Malades Hospital in Paris, scientists from the Cochin Institute (CNRS / INSERM / Paris Descartes University) have discovered that the onset of type 1 diabetes is preceded ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.